{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T03:10:47Z","timestamp":1794971447495,"version":"4.9.1"},"reference-count":141,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.jaad.2020.09.054","type":"journal-article","created":{"date-parts":[[2021,7,28]],"date-time":"2021-07-28T07:35:28Z","timestamp":1627457728000},"page":"956-966","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":140,"title":["Cutaneous adverse events caused by immune checkpoint inhibitors"],"prefix":"10.1016","volume":"85","author":[{"given":"Henry T.","family":"Quach","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas B.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole R.","family":"LeBoeuf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey P.","family":"Zwerner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna K.","family":"Dewan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaad.2020.09.054_bib1","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1200\/JCO.2014.59.4358","article-title":"Immune checkpoint blockade in cancer therapy","volume":"33","author":"Postow","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2020.09.054_bib2","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","article-title":"Safety and activity of anti-PD-L1 antibody in patients with advanced cancer","volume":"366","author":"Brahmer","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2020.09.054_bib3","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1177\/1758834014567469","article-title":"Nivolumab in melanoma: latest evidence and clinical potential","volume":"7","author":"Johnson","year":"2015","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.jaad.2020.09.054_bib4","doi-asserted-by":"crossref","first-page":"2500","DOI":"10.1056\/NEJMc1713444","article-title":"Tumor mutational burden and response rate to PD-1 inhibition","volume":"377","author":"Yarchoan","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2020.09.054_bib5","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1016\/S1470-2045(18)30700-9","article-title":"Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial","volume":"19","author":"Hodi","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jaad.2020.09.054_bib6","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","article-title":"Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma","volume":"378","author":"Motzer","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2020.09.054_bib7","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1001\/jama.2018.13995","article-title":"Immune checkpoint inhibitor toxicity in 2018","volume":"320","author":"Johnson","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.jaad.2020.09.054_bib8","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2020.09.054_bib9","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/s40257-017-0336-3","article-title":"Dermatologic reactions to immune checkpoint inhibitors: skin toxicities and immunotherapy","volume":"19","author":"Sibaud","year":"2018","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.jaad.2020.09.054_bib10","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.currproblcancer.2016.12.001","article-title":"Cutaneous adverse effects of the immune checkpoint inhibitors","volume":"41","author":"Collins","year":"2017","journal-title":"Curr Probl Cancer"},{"key":"10.1016\/j.jaad.2020.09.054_bib11","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1007\/s12254-018-0416-y","article-title":"Management of adverse events related to checkpoint inhibition therapy","volume":"11","author":"Rudzki","year":"2018","journal-title":"Memo"},{"key":"10.1016\/j.jaad.2020.09.054_bib12","doi-asserted-by":"crossref","first-page":"73","DOI":"10.2147\/ITT.S126227","article-title":"Clinical features, predictive correlates, and pathophysiology of immune-related adverse events in immune checkpoint inhibitor treatments in cancer: a short review","volume":"6","author":"Yoest","year":"2017","journal-title":"Immunotargets Ther"},{"key":"10.1016\/j.jaad.2020.09.054_bib13","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/1074-7613(95)90125-6","article-title":"Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4","volume":"3","author":"Tivol","year":"1995","journal-title":"Immunity"},{"key":"10.1016\/j.jaad.2020.09.054_bib14","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.cellimm.2014.05.006","article-title":"The PD-1\/PD-Ls pathway and autoimmune diseases","volume":"290","author":"Dai","year":"2014","journal-title":"Cell Immunol"},{"key":"10.1016\/j.jaad.2020.09.054_bib15","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1001\/jamadermatol.2015.2707","article-title":"Association of vitiligo with tumor response in patients with metastatic melanoma treated with pembrolizumab","volume":"152","author":"Hua","year":"2016","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaad.2020.09.054_bib16","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1046\/j.1523-1747.1998.00354.x","article-title":"Antibody responses to melanoma\/melanocyte autoantigens in melanoma patients","volume":"111","author":"Huang","year":"1998","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaad.2020.09.054_bib17","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1001\/jamaoncol.2019.0402","article-title":"Association of checkpoint inhibitor-induced toxic effects with shared cancer and tissue antigens in non-small cell lung cancer","volume":"5","author":"Berner","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jaad.2020.09.054_bib18","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.jtbi.2014.11.022","article-title":"Unresolved issues in theories of autoimmune disease using myocarditis as a framework","volume":"375","author":"Root-Bernstein","year":"2015","journal-title":"J Theor Biol"},{"key":"10.1016\/j.jaad.2020.09.054_bib19","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1093\/intimm\/dxs098","article-title":"PD-1 is a novel regulator of human B-cell activation","volume":"25","author":"Thibult","year":"2013","journal-title":"Int Immunol"},{"key":"10.1016\/j.jaad.2020.09.054_bib20","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.jaad.2015.10.029","article-title":"Cutaneous adverse events (AEs) of anti-programmed cell death (PD)-1 therapy in patients with metastatic melanoma: a single-institution cohort","volume":"74","author":"Hwang","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2020.09.054_bib21","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1016\/j.jaad.2018.10.062","article-title":"Inflammatory eruptions associated with immune checkpoint inhibitor therapy: a single-institution retrospective analysis with stratification of reactions by toxicity and implications for management","volume":"80","author":"Coleman","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2020.09.054_bib22","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1111\/cup.12876","article-title":"Epidermal programmed cell death-ligand 1 expression in TEN associated with nivolumab therapy","volume":"44","author":"Vivar","year":"2017","journal-title":"J Cutan Pathol"},{"key":"10.1016\/j.jaad.2020.09.054_bib23","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1016\/j.jdcr.2019.07.015","article-title":"Nonbullous pemphigoid secondary to PD-1 inhibition","volume":"5","author":"Singer","year":"2019","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.jaad.2020.09.054_bib24","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1053\/j.seminoncol.2010.09.007","article-title":"The emerging toxicity profiles of anti-CTLA-4 antibodies across clinical indications","volume":"37","author":"Di Giacomo","year":"2010","journal-title":"Semin Oncol"},{"key":"10.1016\/j.jaad.2020.09.054_bib25","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/978-3-030-02505-2_5","article-title":"Skin reactions to immune checkpoint inhibitors","volume":"995","author":"Patel","year":"2018","journal-title":"Adv Exp Med Biol"},{"key":"10.1016\/j.jaad.2020.09.054_bib26","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1111\/jdv.13599","article-title":"ETFAD\/EADV Eczema task force 2015 position paper on diagnosis and treatment of atopic dermatitis in adult and paediatric patients","volume":"30","author":"Wollenberg","year":"2016","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaad.2020.09.054_bib27","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.jaad.2014.07.033","article-title":"Cutaneous adverse effects of targeted therapies: part II: inhibitors of intracellular molecular signaling pathways","volume":"72","author":"Macdonald","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2020.09.054_bib28","first-page":"133","article-title":"Cutaneous side effects of new antitumor drugs: clinical features and management","volume":"109","author":"Gutzmer","year":"2012","journal-title":"Dtsch Arztebl Int"},{"key":"10.1016\/j.jaad.2020.09.054_bib29","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.jdcr.2018.05.001","article-title":"Severe recalcitrant morbilliform eruption from dual immune checkpoint blockade","volume":"4","author":"Fatima","year":"2018","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.jaad.2020.09.054_bib30","doi-asserted-by":"crossref","first-page":"e121","DOI":"10.1016\/j.jaad.2012.12.963","article-title":"The risk of rash associated with ipilimumab in patients with cancer: a systematic review of the literature and meta-analysis","volume":"69","author":"Minkis","year":"2013","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2020.09.054_bib31","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1001\/jamadermatol.2016.2226","article-title":"Clinical and histologic features of lichenoid mucocutaneous eruptions due to anti-programmed cell death 1 and anti-programmed cell death ligand 1 immunotherapy","volume":"152","author":"Shi","year":"2016","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaad.2020.09.054_bib32","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1097\/DAD.0000000000000688","article-title":"Lichenoid dermatologic toxicity from immune checkpoint blockade therapy: a detailed examination of the clinicopathologic features","volume":"39","author":"Tetzlaff","year":"2017","journal-title":"Am J Dermatopathol"},{"key":"10.1016\/j.jaad.2020.09.054_bib33","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jdcr.2016.11.002","article-title":"Inverse lichenoid drug eruption associated with nivolumab","volume":"3","author":"Guggina","year":"2017","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.jaad.2020.09.054_bib34","doi-asserted-by":"crossref","first-page":"e464","DOI":"10.1111\/jdv.14284","article-title":"Oral lichenoid reactions associated with anti-PD-1\/PD-L1 therapies: clinicopathological findings","volume":"31","author":"Sibaud","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaad.2020.09.054_bib35","first-page":"224","article-title":"Nivolumab-induced lichen planus pemphigoides","volume":"103","author":"Strickley","year":"2019","journal-title":"Cutis"},{"key":"10.1016\/j.jaad.2020.09.054_bib36","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1111\/cup.12666","article-title":"Immunohistochemical analysis of lichenoid reactions in patients treated with anti-PD-L1 and anti-PD-1 therapy","volume":"43","author":"Schaberg","year":"2016","journal-title":"J Cutan Pathol"},{"key":"10.1016\/j.jaad.2020.09.054_bib37","doi-asserted-by":"crossref","first-page":"e103","DOI":"10.1634\/theoncologist.2018-0531","article-title":"Resolution of pembrolizumab-associated steroid-refractory lichenoid dermatitis with cyclosporine","volume":"24","author":"Fixsen","year":"2019","journal-title":"Oncologist"},{"key":"10.1016\/j.jaad.2020.09.054_bib38","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1001\/jamaoncol.2015.4368","article-title":"Ipilimumab therapy in patients with advanced melanoma and preexisting autoimmune disorders","volume":"2","author":"Johnson","year":"2016","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jaad.2020.09.054_bib39","doi-asserted-by":"crossref","first-page":"e254","DOI":"10.1111\/jdv.14011","article-title":"Anti-PD1-induced psoriasis: a study of 21 patients","volume":"31","author":"Bonigen","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaad.2020.09.054_bib40","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1097\/CJI.0000000000000121","article-title":"Severe psoriasis flare after anti-programmed death ligand 1 (PD-L1) therapy for metastatic non-small cell lung cancer (NSCLC)","volume":"39","author":"Chia","year":"2016","journal-title":"J Immunother"},{"key":"10.1016\/j.jaad.2020.09.054_bib41","article-title":"A case report of psoriasis flare following immunotherapy: report of an important entity and literature review","volume":"8","author":"Politi","year":"2020","journal-title":"SAGE Open Med Case Rep"},{"key":"10.1016\/j.jaad.2020.09.054_bib42","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1136\/annrheumdis-2017-212257","article-title":"Rheumatic disorders associated with immune checkpoint inhibitors in patients with cancer-clinical aspects and relationship with tumour response: a single-centre prospective cohort study","volume":"77","author":"Kostine","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaad.2020.09.054_bib43","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1097\/CCO.0000000000000296","article-title":"Ocular and orbital side-effects of checkpoint inhibitors: a review article","volume":"28","author":"Antoun","year":"2016","journal-title":"Curr Opin Oncol"},{"key":"10.1016\/j.jaad.2020.09.054_bib44","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1111\/apm.12658","article-title":"Development of de novo psoriasis during nivolumab therapy for metastatic renal cell carcinoma: immunohistochemical analyses and clinical outcome","volume":"125","author":"Ruiz-Ba\u00f1obre","year":"2017","journal-title":"APMIS"},{"key":"10.1016\/j.jaad.2020.09.054_bib45","first-page":"87","article-title":"Drug-induced psoriasis: clinical perspectives","volume":"7","author":"Balak","year":"2017","journal-title":"Psoriasis (Auckl)"},{"key":"10.1016\/j.jaad.2020.09.054_bib46","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.autrev.2018.01.003","article-title":"Rheumatic manifestations among cancer patients treated with immune checkpoint inhibitors","volume":"17","author":"Lidar","year":"2018","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.jaad.2020.09.054_bib47","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.ejca.2019.01.010","article-title":"Successful treatment of psoriasis induced by immune checkpoint inhibitors with apremilast","volume":"110","author":"Fattore","year":"2019","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jaad.2020.09.054_bib48","doi-asserted-by":"crossref","DOI":"10.1177\/2054270418793029","article-title":"Bullous pemphigoid associated with ipilimumab therapy for advanced metastatic melanoma","volume":"9","author":"Hanley","year":"2018","journal-title":"JRSM Open"},{"key":"10.1016\/j.jaad.2020.09.054_bib49","doi-asserted-by":"crossref","first-page":"e21","DOI":"10.1111\/1346-8138.14043","article-title":"Bullous pemphigoid induced by ipilimumab in a patient with metastatic malignant melanoma after unsuccessful treatment with nivolumab","volume":"45","author":"Kuwatsuka","year":"2018","journal-title":"J Dermatol"},{"key":"10.1016\/j.jaad.2020.09.054_bib50","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1158\/2326-6066.CIR-15-0123","article-title":"Autoimmune bullous skin disorders with immune checkpoint inhibitors targeting PD-1 and PD-L1","volume":"4","author":"Naidoo","year":"2016","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.jaad.2020.09.054_bib51","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1111\/ced.13700","article-title":"Linear bullous lichen planus associated with nivolumab","volume":"44","author":"Biolo","year":"2019","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.jaad.2020.09.054_bib52","doi-asserted-by":"crossref","first-page":"268","DOI":"10.3389\/fmed.2018.00268","volume":"5","author":"Zumelzu","year":"2018","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.jaad.2020.09.054_bib53","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1111\/bjd.16780","article-title":"Pembrolizumab-associated mucous membrane pemphigoid in a patient with Merkel cell carcinoma","volume":"179","author":"Haug","year":"2018","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2020.09.054_bib54","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.jdcr.2016.05.009","article-title":"Development of bullous pemphigoid during nivolumab therapy","volume":"2","author":"Damsky","year":"2016","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.jaad.2020.09.054_bib55","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1159\/000487127","article-title":"Intensity-modulated radiotherapy triggers onset of bullous pemphigoid in a patient with advanced melanoma treated with nivolumab","volume":"11","author":"Tanita","year":"2018","journal-title":"Case Rep Oncol"},{"key":"10.1016\/j.jaad.2020.09.054_bib56","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1056\/NEJMoa011592","article-title":"A comparison of oral and topical corticosteroids in patients with bullous pemphigoid","volume":"346","author":"Joly","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2020.09.054_bib57","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1634\/theoncologist.2018-0128","article-title":"A case of nivolumab-induced bullous pemphigoid: review of dermatologic toxicity associated with programmed cell death protein-1\/programmed death ligand-1 inhibitors and recommendations for diagnosis and management","volume":"23","author":"Lopez","year":"2018","journal-title":"Oncologist"},{"key":"10.1016\/j.jaad.2020.09.054_bib58","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1111\/ijd.13970","article-title":"Novel use of combination therapeutic plasma exchange and rituximab in the treatment of nivolumab-induced bullous pemphigoid","volume":"57","author":"Ridpath","year":"2018","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.jaad.2020.09.054_bib59","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/j.jaad.2018.07.008","article-title":"Bullous disorders associated with anti-PD-1 and anti-PD-L1 therapy: a retrospective analysis evaluating the clinical and histopathologic features, frequency, and impact on cancer therapy","volume":"79","author":"Siegel","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2020.09.054_bib60","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1159\/000492172","article-title":"Atezolizumab-induced Stevens-Johnson syndrome in a patient with non-small cell lung carcinoma","volume":"10","author":"Chirasuthat","year":"2018","journal-title":"Case Rep Dermatol"},{"key":"10.1016\/j.jaad.2020.09.054_bib61","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.jdcr.2017.09.028","article-title":"Toxic epidermal necrolysis (TEN) associated with the use of nivolumab (PD-1 inhibitor) for lymphoma","volume":"4","author":"Griffin","year":"2018","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.jaad.2020.09.054_bib62","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1684\/ejd.2017.3023","article-title":"Cutaneous adverse effects during ipilimumab treatment for metastatic melanoma: a prospective study","volume":"27","author":"Dika","year":"2017","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.jaad.2020.09.054_bib63","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1093\/annonc\/mdx640","article-title":"Stevens-Johnson syndrome during nivolumab treatment of NSCLC","volume":"29","author":"Salati","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jaad.2020.09.054_bib64","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.ejca.2017.03.026","article-title":"Pembrolizumab-induced Stevens-Johnson syndrome in non-melanoma patients","volume":"81","author":"Saw","year":"2017","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jaad.2020.09.054_bib65","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1111\/bjd.14530","article-title":"U.K. guidelines for the management of Stevens-Johnson syndrome\/toxic epidermal necrolysis in adults 2016","volume":"174","author":"Creamer","year":"2016","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2020.09.054_bib66","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline","volume":"36","author":"Brahmer","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2020.09.054_bib67","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1001\/jamadermatol.2016.5668","article-title":"Systemic immunomodulating therapies for Stevens-Johnson syndrome and toxic epidermal necrolysis: a systematic review and meta-analysis","volume":"153","author":"Zimmermann","year":"2017","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaad.2020.09.054_bib68","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1177\/1078155217745144","article-title":"Tocilizumab for the management of immune mediated adverse events secondary to PD-1 blockade","volume":"25","author":"Stroud","year":"2019","journal-title":"J Oncol Pharm Pract"},{"key":"10.1016\/j.jaad.2020.09.054_bib69","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.jdcr.2018.11.017","article-title":"Nivolumab-associated DRESS syndrome: a case report","volume":"5","author":"Lu","year":"2019","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.jaad.2020.09.054_bib70","doi-asserted-by":"crossref","first-page":"e53745","DOI":"10.1371\/journal.pone.0053745","article-title":"The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network","volume":"8","author":"Voskens","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.jaad.2020.09.054_bib71","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1097\/CMR.0000000000000326","article-title":"Checkpoint inhibitor-associated drug reaction with eosinophilia and systemic symptom syndrome","volume":"27","author":"Mirza","year":"2017","journal-title":"Melanoma Res"},{"key":"10.1016\/j.jaad.2020.09.054_bib72","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/bjd.13683","article-title":"Histopathology of drug rash with eosinophilia and systemic symptoms syndrome: a morphological and phenotypical study","volume":"173","author":"Ortonne","year":"2015","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2020.09.054_bib73","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1001\/jamadermatol.2015.1916","article-title":"Pembrolizumab cutaneous adverse events and their association with disease progression","volume":"151","author":"Sanlorenzo","year":"2015","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaad.2020.09.054_bib74","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1016\/j.jdcr.2018.08.009","article-title":"Vitiligo in a patient undergoing nivolumab treatment for non-small cell lung cancer","volume":"4","author":"Kosche","year":"2018","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.jaad.2020.09.054_bib75","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.lungcan.2017.04.019","article-title":"Vitiligo in a patient with lung adenocarcinoma treated with nivolumab: a case report","volume":"109","author":"Uenami","year":"2017","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jaad.2020.09.054_bib76","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.jdcr.2016.10.008","article-title":"Nivolumab-associated vitiligo-like depigmentation in a patient with acute myeloid leukemia: a novel finding","volume":"3","author":"Yin","year":"2017","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.jaad.2020.09.054_bib77","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/j.jaad.2016.10.044","article-title":"Vitiligo-like lesions occurring in patients receiving anti-programmed cell death-1 therapies are clinically and biologically distinct from vitiligo","volume":"76","author":"Larsabal","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2020.09.054_bib78","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1007\/s12094-018-1891-7","article-title":"Cutaneous toxicities of new treatments for melanoma","volume":"20","author":"Boada","year":"2018","journal-title":"Clin Transl Oncol"},{"key":"10.1016\/j.jaad.2020.09.054_bib79","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1093\/annonc\/mdp325","article-title":"Vitiligo is an independent favourable prognostic factor in stage III and IV metastatic melanoma patients: results from a single-institution hospital-based observational cohort study","volume":"21","author":"Quaglino","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jaad.2020.09.054_bib80","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1001\/jamaoncol.2019.0046","article-title":"Association of anti-programmed cell death 1 cutaneous toxic effects with outcomes in patients with advanced melanoma","volume":"5","author":"Quach","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jaad.2020.09.054_bib81","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.ejca.2016.02.025","article-title":"Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy","volume":"60","author":"Hofmann","year":"2016","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jaad.2020.09.054_bib82","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1001\/jamadermatol.2018.4560","article-title":"Clinical characterization of immunotherapy-related pruritus among patients seen in 2 oncodermatology clinics","volume":"155","author":"Phillips","year":"2019","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaad.2020.09.054_bib83","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.det.2018.02.010","article-title":"Pruritus associated with targeted anticancer therapies and their management","volume":"36","author":"Wu","year":"2018","journal-title":"Dermatol Clin"},{"key":"10.1016\/j.jaad.2020.09.054_bib84","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1056\/NEJMc1805637","article-title":"PD-1 blockade-induced pruritus treated with a mu-opioid receptor antagonist","volume":"379","author":"Kwatra","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2020.09.054_bib85","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.lungcan.2017.04.020","article-title":"Aprepitant for refractory nivolumab-induced pruritus","volume":"109","author":"Ito","year":"2017","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jaad.2020.09.054_bib86","doi-asserted-by":"crossref","first-page":"e22","DOI":"10.1111\/ced.13825","article-title":"Nivolumab PD-1 inhibitor immunotherapy associated with vulvar, perineal and perianal lichen sclerosus","volume":"44","author":"Wernham","year":"2019","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.jaad.2020.09.054_bib87","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1097\/CAD.0000000000000819","article-title":"An unusual skin reaction in uveal melanoma during treatment with nivolumab: extragenital lichen sclerosus","volume":"30","author":"Veronesi","year":"2019","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.jaad.2020.09.054_bib88","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1001\/jamadermatol.2017.5670","article-title":"Generalized lichen nitidus following anti-PD-1 antibody treatment","volume":"154","author":"Cho","year":"2018","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaad.2020.09.054_bib89","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.jdcr.2017.12.002","article-title":"Lichen planopilaris associated with pembrolizumab in a patient with metastatic melanoma","volume":"4","author":"Cogen","year":"2018","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.jaad.2020.09.054_bib90","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1007\/s10147-019-01490-2","article-title":"Immune checkpoint inhibitor-induced sarcoidosis-like granulomas","volume":"24","author":"Rambhia","year":"2019","journal-title":"Int J Clin Oncol"},{"key":"10.1016\/j.jaad.2020.09.054_bib91","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1111\/cup.13150","article-title":"Dermatologic toxicity from immune checkpoint blockade therapy with an interstitial granulomatous pattern","volume":"45","author":"Trinidad","year":"2018","journal-title":"J Cutan Pathol"},{"key":"10.1016\/j.jaad.2020.09.054_bib92","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/cup.13562","article-title":"Interstitial granulomatous dermatitis and granulomatous arteritis in the setting of PD-1 inhibitor therapy for metastatic melanoma","volume":"47","author":"Singh","year":"2020","journal-title":"J Cutan Pathol"},{"key":"10.1016\/j.jaad.2020.09.054_bib93","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.annder.2017.11.005","article-title":"Two cases of granuloma annulare under anti-PD1 therapy [in French]","volume":"145","author":"Charollais","year":"2018","journal-title":"Ann Dermatol Venereol"},{"key":"10.1016\/j.jaad.2020.09.054_bib94","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1097\/DAD.0000000000001066","article-title":"Granulomatous tumoral melanosis associated with pembrolizumab therapy: a mimicker of disease progression in metastatic melanoma","volume":"40","author":"Woodbeck","year":"2018","journal-title":"Am J Dermatopathol"},{"key":"10.1016\/j.jaad.2020.09.054_bib95","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1002\/ccr3.2090","article-title":"Pembrolizumab-induced sarcoid granulomatous panniculitis and bullous pemphigoid in a single patient","volume":"7","author":"Honigman","year":"2019","journal-title":"Clin Case Rep"},{"key":"10.1016\/j.jaad.2020.09.054_bib96","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1177\/1203475418776934","article-title":"Erythema nodosum as the initial presentation of nivolumab-induced sarcoidosis-like reaction","volume":"22","author":"Laroche","year":"2018","journal-title":"J Cutan Med Surg"},{"key":"10.1016\/j.jaad.2020.09.054_bib97","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.jdcr.2019.01.025","article-title":"Transient eruptive keratoacanthomas associated with nivolumab","volume":"5","author":"Antonov","year":"2019","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.jaad.2020.09.054_bib98","doi-asserted-by":"crossref","first-page":"e28","DOI":"10.1111\/ijd.13893","article-title":"Eruptive keratoacanthomas secondary to nivolumab immunotherapy","volume":"57","author":"Bednarek","year":"2018","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.jaad.2020.09.054_bib99","doi-asserted-by":"crossref","first-page":"97","DOI":"10.4103\/ijdvl.IJDVL_147_18","article-title":"Eruptive squamous cell carcinomas associated with programmed cell death protein-1 inhibitor therapy","volume":"85","author":"Lee","year":"2019","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"10.1016\/j.jaad.2020.09.054_bib100","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1111\/1346-8138.15101","article-title":"Eruptive squamous cell carcinoma in a patient treated with concomitant pembrolizumab and imiquimod","volume":"46","author":"Kanekura","year":"2019","journal-title":"J Dermatol"},{"key":"10.1016\/j.jaad.2020.09.054_bib101","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1111\/bjd.15237","article-title":"Immune-related alopecia (areata and universalis) in cancer patients receiving immune checkpoint inhibitors","volume":"176","author":"Zarbo","year":"2017","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2020.09.054_bib102","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/j.jdcr.2018.05.022","article-title":"Nivolumab-induced alopecia areata: a reversible factor of good prognosis?","volume":"4","author":"Lakhmiri","year":"2018","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.jaad.2020.09.054_bib103","doi-asserted-by":"crossref","first-page":"NP57","DOI":"10.1177\/0300891619872546","article-title":"Unusual skin toxicity associated with sustained disease response induced by nivolumab in a patient with non-small cell lung cancer","volume":"105","author":"Galli","year":"2019","journal-title":"Tumori"},{"key":"10.1016\/j.jaad.2020.09.054_bib104","doi-asserted-by":"crossref","first-page":"262","DOI":"10.3389\/fmed.2019.00262","article-title":"Recurrence of pemphigus vulgaris under nivolumab therapy","volume":"6","author":"Krammer","year":"2019","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.jaad.2020.09.054_bib105","doi-asserted-by":"crossref","first-page":"249","DOI":"10.3389\/fmed.2019.00249","article-title":"Paraneoplastic pemphigus revealed by anti-programmed death-1 pembrolizumab therapy for cutaneous squamous cell carcinoma complicating hidradenitis suppurativa","volume":"6","author":"Yatim","year":"2019","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.jaad.2020.09.054_bib106","first-page":"807","article-title":"Severe oral mucositis: a rare adverse event of pembrolizumab","volume":"17","author":"Lederhandler","year":"2018","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.jaad.2020.09.054_bib107","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1097\/CJI.0000000000000280","article-title":"A severe, refractory case of mucous membrane pemphigoid after treatment with pembrolizumab: brief communication","volume":"42","author":"Bezinelli","year":"2019","journal-title":"J Immunother"},{"key":"10.1016\/j.jaad.2020.09.054_bib108","first-page":"1713","article-title":"Oral mucosal changes induced by anticancer targeted therapies and immune checkpoint inhibitors","volume":"25","author":"Vigarios","year":"2017","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.jaad.2020.09.054_bib109","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1111\/odi.13218","article-title":"Oral immune-related adverse events associated with PD-1 inhibitor therapy: a case series","volume":"26","author":"Shazib","year":"2020","journal-title":"Oral Dis"},{"key":"10.1016\/j.jaad.2020.09.054_bib110","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1111\/bjd.15354","article-title":"A case report of disappearing pigmented skin lesions associated with pembrolizumab treatment for metastatic melanoma","volume":"178","author":"Wolner","year":"2018","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2020.09.054_bib111","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1111\/ijd.14239","article-title":"Multiple \u201chalo nevi\u201d occurring during pembrolizumab treatment for metastatic melanoma","volume":"58","author":"Nicol\u00e9tis-Lombart","year":"2019","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.jaad.2020.09.054_bib112","article-title":"Ipilimumab-associated halo-like inflammatory reactions around nevi during therapy for metastatic melanoma","volume":"24","author":"Alniemi","year":"2018","journal-title":"Dermatol Online J"},{"key":"10.1016\/j.jaad.2020.09.054_bib113","doi-asserted-by":"crossref","first-page":"e121","DOI":"10.1097\/IOP.0000000000001451","article-title":"Development of poliosis following checkpoint inhibitor treatment for cutaneous melanoma","volume":"35","author":"Ediriwickrema","year":"2019","journal-title":"Ophthalmic Plast Reconstr Surg"},{"key":"10.1016\/j.jaad.2020.09.054_bib114","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1016\/j.mayocp.2017.03.016","article-title":"Scleroderma induced by pembrolizumab: a case series","volume":"92","author":"Barbosa","year":"2017","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.jaad.2020.09.054_bib115","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1111\/cup.13273","article-title":"Scleroderma-like skin changes induced by checkpoint inhibitor therapy","volume":"45","author":"Tjarks","year":"2018","journal-title":"J Cutan Pathol"},{"key":"10.1016\/j.jaad.2020.09.054_bib116","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1001\/jamadermatol.2014.2233","article-title":"Drug-associated dermatomyositis following ipilimumab therapy: a novel immune-mediated adverse event associated with cytotoxic T-lymphocyte antigen 4 blockade","volume":"151","author":"Sheik Ali","year":"2015","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaad.2020.09.054_bib117","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.2169\/internalmedicine.9381-17","article-title":"Advanced lung adenocarcinoma with nivolumab-associated dermatomyositis","volume":"57","author":"Kudo","year":"2018","journal-title":"Intern Med"},{"key":"10.1016\/j.jaad.2020.09.054_bib118","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1111\/cup.13059","article-title":"Lupus-like cutaneous reaction following pembrolizumab: an immune-related adverse event associated with anti-PD-1 therapy","volume":"45","author":"Shao","year":"2018","journal-title":"J Cutan Pathol"},{"key":"10.1016\/j.jaad.2020.09.054_bib119","doi-asserted-by":"crossref","first-page":"e152","DOI":"10.1111\/ajd.12681","article-title":"Subacute cutaneous lupus erythematosus induced by nivolumab","volume":"59","author":"Liu","year":"2018","journal-title":"Australas J Dermatol"},{"key":"10.1016\/j.jaad.2020.09.054_bib120","doi-asserted-by":"crossref","first-page":"2579","DOI":"10.1007\/s10067-018-4177-0","article-title":"Vasculitis associated with immune checkpoint inhibitors-a systematic review","volume":"37","author":"Daxini","year":"2018","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.jaad.2020.09.054_bib121","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s40425-018-0321-2","article-title":"Ipilimumab induced digital vasculitis","volume":"6","author":"Padda","year":"2018","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.jaad.2020.09.054_bib122","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1186\/s40425-018-0443-6","article-title":"Immune checkpoint inhibitor-related acral vasculitis","volume":"6","author":"Comont","year":"2018","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.jaad.2020.09.054_bib123","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1186\/s12885-019-5661-x","article-title":"Acral vascular necrosis associated with immune-check point inhibitors: case report with literature review","volume":"19","author":"Khaddour","year":"2019","journal-title":"BMC Cancer"},{"key":"10.1016\/j.jaad.2020.09.054_bib124","doi-asserted-by":"crossref","first-page":"e11","DOI":"10.1016\/j.ejim.2018.07.023","article-title":"Anti-PD1 therapy-associated cutaneous leucocytoclastic vasculitis: a case series","volume":"57","author":"Tomelleri","year":"2018","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.jaad.2020.09.054_bib125","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.jdcr.2018.05.020","article-title":"Checkpoint inhibitor-associated cutaneous small vessel vasculitis","volume":"4","author":"Castillo","year":"2018","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.jaad.2020.09.054_bib126","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2017-223249","article-title":"Autoimmune fasciitis triggered by the anti-programmed cell death-1 monoclonal antibody nivolumab","volume":"2018","author":"Parker","year":"2018","journal-title":"BMJ Case Rep"},{"key":"10.1016\/j.jaad.2020.09.054_bib127","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.jdcr.2019.04.007","article-title":"Nivolumab in non-small cell lung cancer: a novel case of an erythema annulare centrifugum-like eruption","volume":"5","author":"Sidiropoulou","year":"2019","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.jaad.2020.09.054_bib128","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.jdcr.2018.06.022","article-title":"Pityriasis rubra pilaris-like erythroderma in the setting of pembrolizumab therapy responsive to acitretin","volume":"4","author":"Coleman","year":"2018","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.jaad.2020.09.054_bib129","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/s40425-019-0582-4","article-title":"Severe cytokine release syndrome resulting in purpura fulminans despite successful response to nivolumab therapy in a patient with pleomorphic carcinoma of the lung: a case report","volume":"7","author":"Honjo","year":"2019","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.jaad.2020.09.054_bib130","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1111\/ced.13399","article-title":"Sweet syndrome associated with ipilimumab in a patient with metastatic melanoma","volume":"43","author":"Adler","year":"2018","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.jaad.2020.09.054_bib131","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1111\/cup.13492","article-title":"Dermal elastolysis in the setting of combination immunotherapy","volume":"46","author":"Dickinson","year":"2019","journal-title":"J Cutan Pathol"},{"key":"10.1016\/j.jaad.2020.09.054_bib132","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1111\/bjd.18124","article-title":"Acquired generalized lipodystrophy under immune checkpoint inhibition","volume":"182","author":"Haddad","year":"2020","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2020.09.054_bib133","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s40425-019-0534-z","article-title":"Intralymphatic histiocytosis in a patient with lung adenocarcinoma treated with pembrolizumab: a case report","volume":"7","author":"Sugano","year":"2019","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.jaad.2020.09.054_bib134","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1111\/cup.13312","article-title":"Suprabasal acantholytic dermatologic toxicities associated checkpoint inhibitor therapy: a spectrum of immune reactions from paraneoplastic pemphigus-like to Grover-like lesions","volume":"45","author":"Chen","year":"2018","journal-title":"J Cutan Pathol"},{"key":"10.1016\/j.jaad.2020.09.054_bib135","doi-asserted-by":"crossref","first-page":"e54","DOI":"10.1016\/j.cllc.2019.11.009","article-title":"Acute generalized exanthematous pustulosis caused by the combination of pembrolizumab plus chemotherapy in a patient with squamous-cell carcinoma","volume":"21","author":"Matsubara","year":"2020","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.jaad.2020.09.054_bib136","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1111\/cup.13604","article-title":"Ipilimumab\/nivolumab-induced pseudolymphoma in a patient with malignant melanoma","volume":"47","author":"Ayoubi","year":"2020","journal-title":"J Cutan Pathol"},{"key":"10.1016\/j.jaad.2020.09.054_bib137","doi-asserted-by":"crossref","first-page":"e141","DOI":"10.1111\/ijd.14701","article-title":"Eruptive porokeratosis during pembrolizumab treatment of invasive cutaneous squamous cell carcinoma","volume":"59","author":"Maredia","year":"2020","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.jaad.2020.09.054_bib138","doi-asserted-by":"crossref","first-page":"2963","DOI":"10.1200\/JCO.2013.49.5283","article-title":"Challenges of guarantee-time bias","volume":"31","author":"Giobbie-Hurder","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2020.09.054_bib139","doi-asserted-by":"crossref","first-page":"3706","DOI":"10.1002\/cncr.31629","article-title":"High-dose glucocorticoids for the treatment of ipilimumab-induced hypophysitis is associated with reduced survival in patients with melanoma","volume":"124","author":"Faje","year":"2018","journal-title":"Cancer"},{"key":"10.1016\/j.jaad.2020.09.054_bib140","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1200\/JCO.2015.66.1389","article-title":"Safety profile of nivolumab monotherapy: a pooled analysis of patients with advanced melanoma","volume":"35","author":"Weber","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2020.09.054_bib141","doi-asserted-by":"crossref","first-page":"3807","DOI":"10.1200\/JCO.2017.73.2289","article-title":"Efficacy and safety outcomes in patients with advanced melanoma who discontinued treatment with nivolumab and ipilimumab because of adverse events: a pooled analysis of randomized phase II and III trials","volume":"35","author":"Schadendorf","year":"2017","journal-title":"J Clin Oncol"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962220326487?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962220326487?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T23:00:06Z","timestamp":1759273206000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962220326487"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":141,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["S0190962220326487"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2020.09.054","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cutaneous adverse events caused by immune checkpoint inhibitors","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2020.09.054","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 by the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}